New Therapies for Atopic Dermatitis
Shawn Kwatra, M.D., presented new therapies targeting the OX40 pathway, offering hope for atopic dermatitis patients at the Fall Clinical Dermatology meeting.
According to Kwatra, professor and chair of dermatology at the University of Maryland School of Medicine, the OX40 ligand signaling pathway plays a key role in driving chronic inflammation and itching in the skin.
- 16.5 million U.S. adults are affected by atopic dermatitis (AD), the most common form of eczema.
- 9.6 million U.S. children under 18 have AD, with one-third having moderate to severe disease.
Targeting OX40 could help patients with atopic dermatitis.
Author's summary: New OX40 therapies promise hope for atopic dermatitis patients.
More News
- 6 of Trump's Worst Federal Judge Nominations (And What You Can Do)
- Smiling assassins: rows and kowtows with Kevin Rudd • Mark Baker
- 'This is just the beginning' Abu Dhabi House Movement tease big plans as Ministry of Sound hits the capital
- Quote Of The Day, October 29, 2025
- Nominations are open for the 2026 Fed100 awards
- The Mill to relaunch across Europe and Asia under new ownership; reopening studios in London, Seoul and Bangalore, plus US plans
- Lack of investment in Craigavon reflective of DfI ‘disdain’ for local representatives